in vitro News and Research

RSS

Preclinical study shows treatment with DAS181 inhibits infection with multiple HPIV strains

NexBio, Inc. announced today the publication of a "Major Article" in the Journal of Infectious Diseases of a preclinical study showing that treatment with DAS181 (Fludase) inhibits infection with multiple human parainfluenza virus strains. DAS181 is a broad spectrum host-targeted investigational drug candidate for treatment and prevention of Influenza-Like Illness.

19 Jun 2010

Investigators discover new way to harness thrombin's anti-blood clotting properties

In research led by a Saint Louis University investigator, molecular biologists have discovered a way to harness the enzyme thrombin's anti-blood clotting properties. The finding opens the door to new medications that will treat diseases related to thrombosis, the presence of blood clots in blood vessels, which is responsible for nearly a third of all deaths in the U.S.

19 Jun 2010

CardioGenics Holdings files Certificate of Change with the Secretary of State of Nevada

CardioGenics Holdings Inc., developer of the ultra-sensitive QL Care Point-Of-Care analyzer and products for the immunoassay segment of the In-Vitro Diagnostics market, announced today that the Company has filed a Certificate of Change with the Secretary of State of Nevada, which implements a share consolidation of the Company's authorized and outstanding common stock on a ten (old) for one (new) basis.

19 Jun 2010

Children's Hospital Boston receives $2.4M Gates Foundation grant to develop novel neonatal vaccines

Children's Hospital Boston announced today that it has received a $2.4 million grant from the Bill & Melinda Gates Foundation. The grant will support the development of novel vaccines for newborns – research that is spearheaded by Ofer Levy, MD, Ph.D., a principal investigator in the Division of Infectious Diseases at Children's.

18 Jun 2010

Inspire's TIGER-1 Phase 3 clinical trial data with denufosol for CF presented at 33rd ECFS

Inspire Pharmaceuticals, Inc. announced today that data is being presented on denufosol tetrasodium, an investigational therapy for cystic fibrosis (CF), during an oral presentation and poster presentations at the 33rd Annual European Cystic Fibrosis Society (ECFS) Conference June 16 - 19, 2010 in Valencia, Spain.

18 Jun 2010

Vitrolife acquires 25% participation in HertART Aps

Vitrolife has entered an agreement with the Danish company HertART Aps with regard to product development and distribution of IVF products and at the same time acquires a participation of 25 percent in the company.

18 Jun 2010

An ubiquitin-specific peptidase that potentially promote cancer cell necrosis

"ubiquitin-specific peptidase 21 (USP21) has been identified as another essential player in regulation of tumor necrosis factor alpha (TNF-alpha)-induced nuclear factor kappaB (NF-kappaB) activation by working on receptor-interacting protein 1(RIP1)."

18 Jun 2010

Bayer, OncoMed collaborate to develop anti-cancer stem cell therapeutics to target Wnt signaling pathway

Bayer Schering Pharma AG and OncoMed Pharmaceuticals, Inc., today announced a global strategic alliance to discover, develop and commercialize novel anti-cancer stem cell therapeutics targeting the Wnt signaling pathway.

17 Jun 2010

FDA seeks public input on regulation of laboratory-developed tests

The U.S. Food and Drug Administration today announced plans to hold a public meeting on July 19-20, 2010, to discuss how the agency will oversee laboratory-developed tests (LDTs).

17 Jun 2010

Researchers assess effect of MDs on cardiac and endothelial cell proliferation, survival

A research team from McGill University (Canada) report a beneficial effect on cardiac function in mouse models when implanted monocytes - a type of white blood cell that is part of the immune system - helped preserve cardiac function following a heart attack (myocardial infarction).

17 Jun 2010

Fertility drugs cause multiple and premature births

The widespread use of fertility drugs, not just high-tech laboratory procedures, plays a major role in causing multiple births and contributes to the problem of premature birth in the United States, experts said today at the March of Dimes National Communications Advisory Council luncheon.

17 Jun 2010

Oncodesign announces technology license agreement with Janssen Pharmaceutica

Oncodesign Biotechnology(R) announced today that it has signed a licensing agreement with Janssen Pharmaceutica NV (hereinafter Janssen) related to Janssen’s macrocyclic chemistry technology. Oncodesign will have exclusive access to this technology for six years.

16 Jun 2010

Animal-free testing method for human-specific allergenicity displayed at 2010 ICCA-LRI & JRC Workshop

For the first time, Sweden-based Biovator AB and its cooperation partners will reveal the crucial aspects of the company's unique, animal-free testing method for human-specifi c allergenicity. A detailed presentation is being created for participants in the 2010 ICCA-LRI & JRC Workshop (International Council of Chemical Associations Long-Range Research Initiative), which will take place June 16-17, 2010 at the Grand Hotel Bristol in Stresa, Italy.

16 Jun 2010

Epocal receives FDA marketing clearance for new lactate test on epoc Blood Analysis System

Epocal, Inc., a leading edge provider of point of care technology, announced today that it has received U.S. Food and Drug Administration (FDA) clearance to market its new lactate test on the epoc Blood Analysis System. Lactate measurements from the epoc System are used to evaluate acid-base status and for diagnosis and treatment of lactic acidosis (abnormally high acidity of the blood).

15 Jun 2010

CDI, Promega enter collaboration for toxicity testing in drug discovery process

Cellular Dynamics International (CDI) and Promega have entered into a research collaboration with the goal of bringing more relevant and highly predictive toxicity testing to the drug discovery process. Pharmaceutical discovery scientists will now be able to combine bioassays with human cardiomyocytes to improve prediction of unintentional, detrimental side effects that have previously remained undetected until late in the development process or after release of the drug to the general public.

15 Jun 2010

Tel Aviv University research suggests link between IVF treatments and autism

The first "test tube baby" was born in 1978. With advances in reproductive science, an estimated one percent of all American babies are now born each year through in vitro fertilization. But IVF and other assisted fertility treatments may be solving one problem by creating another, suggests new evidence from Tel Aviv University.

15 Jun 2010

MP Biomedicals to acquire ICPbio International

MP Biomedicals LLC announced today that it has signed a definitive agreement to acquire the assets of ICPbio International LTD., an Auckland, New Zealand based protein biologics manufacturing company, subject to normal closing adjustments. This acquisition places MP Biomedicals in a strong position to pursue sales and distribution of serum protein products used in research and manufacturing in the Biopharmaceutical, In vitro diagnostic and Biotech sectors.

From MP Biomedicals, LLC 14 Jun 2010

Calistoga Pharmaceuticals presents CAL-101 PI3K inhibitor data at European Hematology Association Congress

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today presented preclinical and clinical data on CAL-101, the Company's oral, delta selective PI3K inhibitor at the 15th Congress of the European Hematology Association in Barcelona, Spain.

14 Jun 2010

Children born after ART at increased risk of congenital malformation

Couples considering undergoing assisted reproductive technology (ART) treatment should be informed about the increased risk of congenital malformation posed by the use of ART, the annual conference of the European Society of Human Genetics will hear today (Monday). Dr. G-raldine Viot, a clinical geneticist at the Maternit- Port Royal hospital, Paris, France, will say that she believed that most doctors working in ART clinics in France only told couples about such risks if they were asked specific questions.

14 Jun 2010

In vitro fertilization ups the risk of birth defects: study

Researchers have found from a large scale study that in vitro fertilization of IVF is associated with an increased risk of birth defects in the baby. They urge doctors treating patients with infertility to routinely warn them about these risks. The study involved 33 centers for IVF in France and covered over 15,000 births from 2003 to 2007. This study is the largest till date.

14 Jun 2010

in vitro News and Research

Preclinical study shows treatment with DAS181 inhibits infection with multiple HPIV strains

Investigators discover new way to harness thrombin's anti-blood clotting properties

CardioGenics Holdings files Certificate of Change with the Secretary of State of Nevada

Children's Hospital Boston receives $2.4M Gates Foundation grant to develop novel neonatal vaccines

Inspire's TIGER-1 Phase 3 clinical trial data with denufosol for CF presented at 33rd ECFS

Vitrolife acquires 25% participation in HertART Aps

An ubiquitin-specific peptidase that potentially promote cancer cell necrosis

Bayer, OncoMed collaborate to develop anti-cancer stem cell therapeutics to target Wnt signaling pathway

FDA seeks public input on regulation of laboratory-developed tests

Researchers assess effect of MDs on cardiac and endothelial cell proliferation, survival

Fertility drugs cause multiple and premature births

Oncodesign announces technology license agreement with Janssen Pharmaceutica

Animal-free testing method for human-specific allergenicity displayed at 2010 ICCA-LRI & JRC Workshop

Epocal receives FDA marketing clearance for new lactate test on epoc Blood Analysis System

CDI, Promega enter collaboration for toxicity testing in drug discovery process

Tel Aviv University research suggests link between IVF treatments and autism

MP Biomedicals to acquire ICPbio International

Calistoga Pharmaceuticals presents CAL-101 PI3K inhibitor data at European Hematology Association Congress

Children born after ART at increased risk of congenital malformation

In vitro fertilization ups the risk of birth defects: study

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News